The Food and Drug Administration (FDA) granted traditional approval of a disease-modifying treatment that could potentially give some patients with Alzheimer’s disease something they haven’t had before: a medication that may slow the decline of memory and thinking.
A monoclonal antibody, lecanemab, shows promise in removing amyloid plaques from the brain, according to phase 3 trial results. Amyloid plaques are one of the defining features of Alzheimer’s disease, according to Dr. Ronald Petersen, a neurologist and director of the Mayo Clinic Alzheimer’s Disease Research Center.
Watch: Dr. Petersen discusses FDA approval
Journalists: Broadcast-quality video is available in the downloads at the end of the post. Please courtesy: Mayo Clinic News Network. Name super/CG: Ronald Petersen, M.D., Ph.D./Alzheimer’s Disease Research Center/Mayo Clinic.
“Amyloid is one of the key proteins involved in Alzheimer’s disease. It’s thought that by removing amyloid from the brain, you will slow down the rate of progression of the disease. Now, importantly, it doesn’t stop the disease. It doesn’t make people better, but it will slow down the rate at which the disease progresses so people remain functional for a longer period of time,” says Dr. Petersen.
Brain changes associated with Alzheimer’s disease can lead to growing trouble with:
- Memory
- Thinking and reasoning
- Making judgments and decisions
- Planning and performing familiar tasks
- Changes in personality and behavior
As with any drug, Dr. Petersen says lecanemab has potential side effects which can be serious. Who would be a good candidate for this treatment?
“Lecanemab does, in fact, remove amyloid from the brain, but it may also remove amyloid from the blood vessels in the brain,” he explains. “This may render them leaky, such that people on this drug may develop some swelling in the brain and may develop some bleeding in the brain. This can be monitored by MRI, and usually the side effects have been mild and moderate.”
Dr. Petersen says the data from the lecanemab study were an important step forward in the fight against a disease which robs patients of their most human qualities.
“It shows that we now may have the ability to actually modify the underlying disease process. Heretofore, we’ve had symptomatic drugs for Alzheimer’s disease, but they do not actually get at the underlying disease process. Drugs like lecanemab now actually alter the disease process itself and will slow down the rate of progression. That’s a major step forward,” says Dr. Petersen.
“This gives us an opportunity to perhaps add other drugs that may have additive mechanisms of action to actually slow down the disease process even more dramatically.”
Who would be a good candidate for this treatment?
Dr. Petersen says it’s important to note that this treatment is not intended for all dementia patients.
“It’s likely that lecanemab will be used for people who have the mildly symptomatic phases of Alzheimer’s disease. So clinically, we call that mild cognitive impairment or mild dementia due to Alzheimer’s disease. These were the people who are actually involved in the phase 3 clinical trial that demonstrated the effectiveness of the drug.”
Disclosures:
Dr. Petersen has previously consulted with Biogen and Eisai, makers of lecanemab. He was not involved in the design or execution of clinical trials for lecanemab.
Read more about Alzheimer’s disease and dementia:
Related posts:
